Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Tscan Therapeutics stock
Learn how to easily invest in Tscan Therapeutics stock.
Tscan Therapeutics Inc is a biotechnology business based in the US. Tscan Therapeutics shares (TCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Tscan Therapeutics employs 90 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Tscan Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – TCRX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Tscan Therapeutics stock price (NASDAQ: TCRX)Use our graph to track the performance of TCRX stocks over time.
Tscan Therapeutics shares at a glance
|Latest market close||$4.85|
|52-week range||$4.18 - $14.71|
|50-day moving average||$6.62|
|200-day moving average||$7.95|
|Wall St. target price||$21.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.14|
Buy Tscan Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Tscan Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Tscan Therapeutics price performance over time
|1 week (2022-01-12)||3.19%|
|1 month (2021-12-20)||6.83%|
|3 months (2021-10-20)||-31.69%|
|6 months (2021-07-20)||-54.29%|
|1 year (2021-01-16)||N/A|
|2 years (2020-01-16)||N/A|
|3 years (2019-01-16)||N/A|
|5 years (2017-01-16)||N/A|
Tscan Therapeutics financials
|Revenue TTM||$8.1 million|
|Gross profit TTM||$-19,492,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$111.7 million|
TTM: trailing 12 months
Tscan Therapeutics share dividends
We're not expecting Tscan Therapeutics to pay a dividend over the next 12 months.
Tscan Therapeutics overview
TScan Therapeutics, Inc. , a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Tscan Therapeutics in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Tscan Therapeutics is owned by insiders or institutions?
Currently 25.673% of Tscan Therapeutics shares are held by insiders and 59.872% by institutions. How many people work for Tscan Therapeutics?
Latest data suggests 90 work at Tscan Therapeutics. When does the fiscal year end for Tscan Therapeutics?
Tscan Therapeutics's fiscal year ends in December. Where is Tscan Therapeutics based?
Tscan Therapeutics's address is: 830 Winter Street, Waltham, MA, United States, 02451 What is Tscan Therapeutics's ISIN number?
Tscan Therapeutics's international securities identification number is: US89854M1018
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert